Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
both cell line- and patient-derived BRAFV600E tumors exhibit stronger and more sustained pharmacodynamic inhibition (>90% for 8 hours) and improved survival compared to mutant KRAS-expressing tumors
InChiKey: WEIAMZKHBCLFOG-QPAIBFMUSA-N
3-b]quinolin-4-yl}-2-(2-oxopyrrolidin-1-yl)acetamide
It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides
Formula: C18H27N3O6S
SB-269970 3022 both cell line- and patient-derivedSB269970 HCl is a potent 5 HT7A antagonist (pKi = 8. 9) that demonstrates >50 fold binding selectivity over 5 HT5A and >250 fold selectivity over 5 HT1, 5 HT2, 5 HT4, 5 HT6, adrenergic 1, dopamine D2, and dopamine D3 receptors. It is also reported to block adrenergic 2 receptors in guinea pig vas deferens. SB 269970 has been used to target the 5 HT7 receptor in the study of schizophrenia like cognitive deficits. Product information CAS Number: 201038
US$ 85.00
US$ 85.00
US$ 112.50
US$ 45.00
US$ 205.50
US$ 120.00
US$ 140.50
US$ 175.00
US$ 150.00
US$ 35.00